In October 2025, the U.S. FDA approved Bayer’s non-hormonal drug Lynkuet (elinzanetant). This is the world’s first approved NK1/NK3 receptor antagonist specifically for the treatment of moderate to severe hot flashes during menopause. This represents a significant medical breakthrough for women who cannot use hormone therapy due to illness, and has sparked global attention to “precision medicine for menopause.”

https://www.pharmacytimes.com/view/fda-approves-elinzanetant-as-first-nonhormonal-therapy-for-menopause-vasomotor-symptoms